Belgium has reserved 2.9 million doses of the future vaccine against the coronavirus from the company CureVac in order to buy it if it receives all the necessary authorizations, the interministerial public health conference indicated on Tuesday.
The European Commission had validated a pre-purchase contract last week with CureVac, a pharmaceutical company based in Germany and chaired by the Belgian Jean Stéphenne. This European contract covers 225 million doses, with an option for additional doses, up to 180 million.
Member States can subscribe to it and thus obtain reservations in proportion to their population.
If this vaccine obtains a marketing authorization, Belgium will buy it, confirmed Tuesday the Interministerial Conference on Public Health, after opinion of the advisory committee responsible for analyzing the purchase files.
CureVac is not alone on the list of Belgian authorities. In mid-August, the advisory committee had already given a positive opinion for the contract for the vaccine candidate of AstraZeneca and the University of Oxford and, in November 2020, for those of Janssen (Johnson & Johnson) and Pfizer and BioNTech.
Clinical trials with the CureVac vaccine are underway in Europe, also in Belgium.
The marketing authorization, for its part, remains a competence of the European Medicines Agency (EMA) in cooperation with the national authorities. If the authorization is not granted by the EMA, the contract will be dissolved. There is no approved vaccine against Covid-19 yet.